Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

171 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

dbGaP phs000828 Genomic Analysis of Hepatocellular Carcinoma - Eligibility

- 04/03/2024 - 4 Formulaires, 1 Groupe Item, 5 Eléments de données, 1 Langue
Groupe Item: IG.elig
Principal Investigator: Julien Sage, PhD, Departments of Pediatrics and Genetics, Stanford University, Stanford, CA, USA MeSH: Fibrolamellar hepatocellular carcinoma,Carcinoma, Hepatocellular https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000828 Fibrolamellar hepatocellular carcinoma (FL-HCC) is a very rare and distinct subtype of hepatocellular carcinoma that occurs in the previously healthy livers of adolescents and young adults. The low incidence rate has kept FL-HCC an understudied cancer, thus the list of FL-HCC markers is limited and the genetic alterations driving its growth have remained unknown. In order to gain a better understanding of the molecular mechanisms underlying FL-HCC initiation and progression, we performed an in-depth genomic analyses of one tumor followed by immunohistochemistry validation on seven other tumors. We showed the expression of neuroendocrine markers in FL-HCC. In addition, DNA/RNA sequencing revealed that common cancer pathways are not visibly altered in FL-HCC but identified two novel structural variants, both resulting in fusion transcripts. Through in vitro studies, we demonstrated the oncogenic properties of these fusion transcripts. These experiments further highlight the tumorigenic role of gene fusions in the etiology of pediatric solid tumors and identify both candidate biomarkers and possible therapeutic targets for this lethal pediatric disease.

pht004327.v1.p1

1 Groupe Item 3 Eléments de données

pht004328.v1.p1

1 Groupe Item 3 Eléments de données

pht004329.v1.p1

1 Groupe Item 8 Eléments de données

dbGaP phs001199 TIGER-LC OncoVar Sequencing - Eligibility

- 25/05/2023 - 5 Formulaires, 1 Groupe Item, 1 Élément de données, 1 Langue
Groupe Item: IG.elig
Principal Investigator: Xin Wei Wang, PhD, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA MeSH: Carcinoma, Hepatocellular,Cholangiocarcinoma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001199 Intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are clinically disparate primary liver cancers with etiological and biological heterogeneity. We performed targeted sequencing of Thai ICC and HCC among the Thailand Initiative in Genomics and Expression Research for Liver Cancer (TIGER-LC) cohort using the OncoVar platform.

pht005704.v1.p1

1 Groupe Item 5 Eléments de données

pht005705.v1.p1

1 Groupe Item 5 Eléments de données

pht005706.v1.p1

1 Groupe Item 3 Eléments de données

pht005707.v1.p1

1 Groupe Item 6 Eléments de données

dbGaP phs000709 The Genome and Transcriptome of Fibrolamellar Hepatocellular Carcinoma - pht003813.v1.p1

- 14/12/2022 - 4 Formulaires, 1 Groupe Item, 3 Eléments de données, 1 Langue
Groupe Item: pht003813
Principal Investigator: Sanford Simon, PhD, The Rockefeller University, New York, NY, USA MeSH: Fibrolamellar hepatocellular carcinoma,Carcinoma, Hepatocellular https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000709 Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare liver tumor primarily affecting adolescents and young adults. Little is known of the molecular pathogenesis. To characterize the disease we performed RNA sequencing and whole genome sequencing on FL-HCC tumors and adjacent normal tissue. The results demonstrate few consistent differences on the chromosomal level and many hundreds of alterations in the expression of RNA transcripts.

pht003814.v1.p1

1 Groupe Item 7 Eléments de données

Eligibility

1 Groupe Item 1 Élément de données

pht003812.v1.p1

1 Groupe Item 2 Eléments de données

dbGaP phs000509 Genome Sequencing of Hepatocellular Carcinoma - Eligibility

- 13/12/2022 - 5 Formulaires, 1 Groupe Item, 1 Élément de données, 1 Langue
Groupe Item: IG.elig
Principal Investigator: Marie-Claude Gingras, PhD, Baylor College of Medicine, Human Genome Sequencing Center, Houston, TX, USA MeSH: Carcinoma, Hepatocellular https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000509 Hepatocellular carcinoma (HCC) accounts for 85-90% of primary liver cancers. We have focused on three major HCC etiologies:hepatitis C virus (HCV), hepatitis B virus (HBV), and nonviral causes. The onset and progression of cancer is driven by extensive rearrangement and mutation of the genome. We combined our capability to capture and enrich exome DNA with the next generation sequencing capacity to allow us to detect and characterize the somatic mutation profile of patients with HCC. Patient samples were collected by the Liver Center, Division of Abdominal Transplantation in the Baylor College of Medicine Department of Surgery. Sequencing of HCC is one of the NHGRI Center Initiated Projects in progress in the Human Genome Sequencing Center at Baylor College of Medicine.

pht004312.v1.p1

1 Groupe Item 5 Eléments de données

pht004313.v1.p1

1 Groupe Item 5 Eléments de données

pht004314.v1.p1

1 Groupe Item 8 Eléments de données

pht004315.v1.p1

1 Groupe Item 4 Eléments de données

dbGaP phs000384 Genentech Whole Genome Sequencing of Four Hepatocellular Carcinoma Patients - Eligibility

- 12/10/2022 - 5 Formulaires, 1 Groupe Item, 1 Élément de données, 1 Langue
Groupe Item: IG.elig
Principal Investigator: Zemin Zhang, PhD, Genentech Inc., San Francisco, CA, USA MeSH: Hepatocellular Carcinomas,Hepatitis B https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000384 Hepatitis B virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC). In this study we sequenced the whole genome (~80X) and transcriptome of tumor and non-tumor samples from four HCC patients and identified over two hundred HBV integration sites. We found significant clonal expansion of HBV-integrated hepatocytes specifically in the tumor samples. We observed a diverse collection of genomic perturbations near viral integration sites, including gene disruption, viral promoter-driven human transcription, viral-human transcript fusion and DNA copy number alteration. We also sequenced one patient at ultra-high coverage (~240X) to build the most comprehensive HBV-integration landscape yet attempted. Our data suggest that the viral integration significantly expands carcinogenic opportunities in HBV-infected individuals.

pht002461.v1.p1

1 Groupe Item 3 Eléments de données

pht002462.v1.p1

1 Groupe Item 3 Eléments de données

pht002463.v1.p1

1 Groupe Item 5 Eléments de données

pht002464.v1.p1

1 Groupe Item 9 Eléments de données

Eligibility NCT01246986 Carcinoma - Eligibility

- 27/09/2021 - 1 Formulaire, 2 Groupes Item, 27 Eléments de données, 2 Langues
Groupes Item: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01246986

Eligibility Advanced Adult Hepatocellular Carcinoma NCT02418988

- 27/09/2021 - 1 Formulaire, 2 Groupes Item, 19 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02418988

Eligibility Hepatocellular Carcinoma NCT00862082

- 27/09/2021 - 1 Formulaire, 2 Groupes Item, 19 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC); ODM derived from: https://clinicaltrials.gov/show/NCT00862082

Eligibility Hepatocellular Carcinoma NCT00669136

- 27/09/2021 - 1 Formulaire, 2 Groupes Item, 21 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00669136

Eligibility Hepatocellular Carcinoma NCT01686880

- 27/09/2021 - 1 Formulaire, 2 Groupes Item, 19 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver; ODM derived from: https://clinicaltrials.gov/show/NCT01686880

Eligibility Hepatocellular Carcinoma NCT01658878

- 27/09/2021 - 1 Formulaire, 3 Groupes Item, 12 Eléments de données, 1 Langue
Groupes Item: Criteria, Inclusion Criteria, Exclusion Criteria
Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma); ODM derived from: https://clinicaltrials.gov/show/NCT01658878

Eligibility Hepatocellular Carcinoma NCT01575574

- 27/09/2021 - 1 Formulaire, 2 Groupes Item, 12 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis; ODM derived from: https://clinicaltrials.gov/show/NCT01575574

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial